ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics primarily for organ transplantation and stem cell transplantation. The lead candidate drug Siplizumab is a monoclonal antibody in late-stage clinical development, which has shown significant potential in revolutionizing the treatment of organ transplant patients, by allowing the complete discontinuation of all immunosuppressive drugs and restoration of a normal life.